July 8th 2025
New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.
ICAAC: Integrase Inhibitor Effective for HIV Patients with Multi-drug Resistant Disease
September 18th 2007CHICAGO -- The investigative integrase inhibitor raltegravir (Isentress) can suppress the viral load to undetectable levels in at least half of HIV patients with virus resistant to three drug classes, researchers said here.
Warning Issued on Nelfinavir (Viraceprt) for Children and Pregnant Women
September 10th 2007NEW YORK -- In the wake of a recall in Europe of nelfinavir (Viracept) because of a potentially carcinogenic impurity, Pfizer has issued new guidelines for the anti-retroviral drug's use in the U.S., the FDA reported.
New Lymphadenopathy in a Woman With a History of Colon Cancer
September 1st 2007A 47-year-old woman who recently completed adjuvant chemotherapy for colon cancer has painless cervical lymphadenopathy of 1 to 2 cm. She has no fever, sore throat, cough, or unexplained weight loss, and she denies exposure to ill persons or animals.
IAS: CCR5 Inhibitors Eagerly Awaited for HIV Therapy
July 27th 2007SYDNEY -- A new class of HIV drugs, the CCR5 inhibitors, is designed to prevent HIV from entering cells and should be helpful in disease management if they gain regulatory approval, said researchers at an industry-sponsored symposium here.